DE2610886A1 - Verbindungen mit antidepressiver wirkung - Google Patents

Verbindungen mit antidepressiver wirkung

Info

Publication number
DE2610886A1
DE2610886A1 DE19762610886 DE2610886A DE2610886A1 DE 2610886 A1 DE2610886 A1 DE 2610886A1 DE 19762610886 DE19762610886 DE 19762610886 DE 2610886 A DE2610886 A DE 2610886A DE 2610886 A1 DE2610886 A1 DE 2610886A1
Authority
DE
Germany
Prior art keywords
formula
compound
group
compounds
oxime
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE19762610886
Other languages
German (de)
English (en)
Other versions
DE2610886C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html
Inventor
Volkert Claassen
Hendricus Bernardus Anto Welle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Koninklijke Philips NV
Original Assignee
Philips Gloeilampenfabrieken NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philips Gloeilampenfabrieken NV filed Critical Philips Gloeilampenfabrieken NV
Publication of DE2610886A1 publication Critical patent/DE2610886A1/de
Application granted granted Critical
Publication of DE2610886C2 publication Critical patent/DE2610886C2/de
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/50—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals
    • C07C251/58—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C249/00—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C249/04—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes
    • C07C249/08—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes by reaction of hydroxylamines with carbonyl compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE19762610886 1975-03-20 1976-03-16 Verbindungen mit antidepressiver wirkung Granted DE2610886A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL7503310A NL7503310A (nl) 1975-03-20 1975-03-20 Verbindingen met antidepressieve werking.

Publications (2)

Publication Number Publication Date
DE2610886A1 true DE2610886A1 (de) 1976-10-07
DE2610886C2 DE2610886C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1987-09-24

Family

ID=19823424

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19762610886 Granted DE2610886A1 (de) 1975-03-20 1976-03-16 Verbindungen mit antidepressiver wirkung

Country Status (27)

Country Link
US (1) US4085225A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS6026776B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (2) AR211011A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) AT340895B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU505358B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE839744A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1076142A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH (4) CH626057A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DD (1) DD128332A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE2610886A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK144942C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES446192A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI61875C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2304336A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB1535226A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR60052B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU171030B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE43768B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL49238A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT (1) IT1063064B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9203723A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL7503310A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (3) PL100614B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SE (1) SE410312B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SU (3) SU635867A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
YU (1) YU39345B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA761434B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1110460B (it) * 1977-03-02 1985-12-23 Ciba Geigy Ag Prodotti che favoriscono la crescita delle piante e prodotti che proteggono le piante a base di eteri di ossime e di esteri di ossime loro preparazione e loro impiego
FR2639942B1 (fr) * 1988-12-02 1991-03-29 Sanofi Sa Ethers oximes de propenone, procede pour leur preparation et compositions pharmaceutiques les contenant
US5665756A (en) * 1994-08-03 1997-09-09 Hoechst Marion Roussel, Inc. Aminoalkyloximes useful in the treatment of depression and obsessive compulsive disorders
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
ES2145977T3 (es) * 1995-08-16 2000-07-16 Lilly Co Eli Potenciacion de la respuesta de la serotonina.
IN182588B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1998-05-12 1999-05-08 Sun Pharmaceutical Ind Ltd
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
IN186677B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1999-11-12 2001-10-20 Sun Pharmaceutical Ind Ltd
US20080021085A1 (en) * 2000-04-13 2008-01-24 Mayo Foundation For Medical Education And Research Method of reducing abeta42 and treating diseases
EP1284729A4 (en) * 2000-04-13 2007-12-19 Mayo Foundation REDUCTION AGENTS OF A (BETA) 42
US6469064B2 (en) * 2000-04-24 2002-10-22 Aryx Therapeutics Materials and methods for the treatment of depression
US7256191B2 (en) * 2000-04-24 2007-08-14 Aryx Therapeutics Materials and methods for the treatment of depression
WO2003079972A2 (en) 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
WO2003031407A2 (en) * 2001-10-12 2003-04-17 Serenix Pharmaceuticals, Llc β-LACTAMYL VASOPRESSIN VlaANTAGONISTS
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
JP2007528857A (ja) * 2003-07-11 2007-10-18 ミリアド ジェネティクス， インコーポレイテッド アルツハイマー病の処置のための薬学的方法、投与レジメンおよび投薬形態
NZ545494A (en) 2003-09-12 2009-10-30 Pfizer Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
DE602004028150D1 (de) * 2003-11-26 2010-08-26 Pfizer Prod Inc Aminopyrazolderivate als gsk-3-inhibitoren
PL1691811T3 (pl) 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
EP1737473A4 (en) * 2004-04-19 2009-08-26 Noven Therapeutics Llc COMBINATIONS OF LITHIUM AND USES THEREOF
WO2005108683A1 (en) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
AU2006227199A1 (en) 2005-03-22 2006-09-28 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids for treating premenstrual disorders
MX2007013021A (es) * 2005-04-22 2008-01-11 Wyeth Corp Derivados de benzofuranil-alcanamina y usos de los mismos como agonistas de 5-ht2c.
US7402687B2 (en) 2005-04-22 2008-07-22 Wyeth Dihydrobenzofuran derivatives and uses thereof
PE20070093A1 (es) * 2005-04-22 2007-02-07 Wyeth Corp Derivados dihidrobenzofuranos como moduladores del receptor 5-ht2c
AU2006239897A1 (en) * 2005-04-22 2006-11-02 Wyeth Crystal forms of {[(2R)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
CA2614289A1 (en) * 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
WO2007011878A2 (en) * 2005-07-19 2007-01-25 Azevan Pharmaceuticals, Inc. Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
EP1909777A2 (en) * 2005-07-22 2008-04-16 Myriad Genetics, Inc. High drug load formulations and dosage forms
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
BRPI0709159A2 (pt) * 2006-03-24 2011-06-28 Wyeth Corp combinações terapêuticas para o tratamento de depressão
JP4615470B2 (ja) * 2006-03-29 2011-01-19 卓郎 簑和田 大脳の認知力を用いた疾患治療・予防の方法および医薬
AU2007249435A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 HT receptor mediated neurogenesis
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2008006099A2 (en) * 2006-07-07 2008-01-10 Myriad Genetics, Inc. Treatment of psychiatric disorders
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
BRPI0716604A2 (pt) 2006-09-08 2013-04-09 Braincells Inc combinaÇÕes contendo um derivado de 4-acilaminopiridina
US20100016274A1 (en) * 2006-09-14 2010-01-21 Koppel Gary A Beta-lactam cannabinoid receptor modulators
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
WO2008086483A2 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation of neurogenesis with use of modafinil
EP2288345B1 (en) 2008-04-18 2015-06-10 University College Dublin National University Of Ireland, Dublin Psycho-pharmaceuticals
WO2010021681A2 (en) * 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
HRP20160781T1 (hr) 2009-10-23 2016-09-23 Janssen Pharmaceutica N.V. DISUPSTITUIRANI OKTAHIDROPIROLO[3,4-c]PIROLI KAO MODULATORI OREKSIN RECEPTORA
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
ES2858499T3 (es) 2010-07-01 2021-09-30 Azevan Pharmaceuticals Inc Compuestos para su uso en el tratamiento de trastorno explosivo intermitente
AU2012227936A1 (en) 2011-03-17 2013-10-17 Lupin Limited Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
KR101427221B1 (ko) * 2012-08-29 2014-08-13 주식회사 에스텍파마 플루복사민 자유 염기의 정제방법 및 이를 이용한 고순도 플루복사민 말레이트의 제조방법
IN2013MU01290A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 2013-04-03 2015-04-10 Zcl Chemicals Ltd
US10124006B2 (en) 2014-02-07 2018-11-13 MTA Tämogatott Kutatócsoportok Irodája Use of Sigma-1 receptor agonist compounds
MY184878A (en) 2014-03-28 2021-04-29 Azevan Pharmaceuticals Inc Compositions and methods for treating neurodegenerative diseases
PT3426251T (pt) * 2016-03-10 2022-07-27 Janssen Pharmaceutica Nv Métodos de tratamento da depressão utilizando antagonistas dos recetores de orexina-2
DK3544420T3 (da) 2016-11-24 2022-09-05 Sigmadrugs Kutato Korlatolt Feleloessegue Tarsasag Anvendelse af sammensætninger til organ-/vævskonservering
BR112020005107A2 (pt) 2017-09-15 2020-11-03 Azevan Pharmaceuticals, Inc. composições e métodos para o tratamento de lesão cerebral
CA3145388A1 (en) 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1768100A1 (de) * 1967-04-05 1971-10-14 Duphar Int Res Verbindungen mit pharmakologischen Eigenschaften

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1768100A1 (de) * 1967-04-05 1971-10-14 Duphar Int Res Verbindungen mit pharmakologischen Eigenschaften

Also Published As

Publication number Publication date
DK144942C (da) 1982-12-06
SE7603341L (sv) 1976-09-21
ES446192A1 (es) 1977-10-01
SU635867A3 (ru) 1978-11-30
DD128332A5 (de) 1977-11-09
DK115976A (da) 1976-09-21
SU645559A3 (ru) 1979-01-30
FI760699A7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1976-09-21
AU505358B2 (en) 1979-11-15
YU71476A (en) 1982-10-31
AR211153A1 (es) 1977-10-31
NL7503310A (nl) 1976-09-22
GR60052B (en) 1978-04-04
PL101951B1 (pl) 1979-02-28
IE43768L (en) 1976-09-20
YU39345B (en) 1984-10-31
IL49238A0 (en) 1976-05-31
CA1076142A (en) 1980-04-22
ATA195476A (de) 1977-05-15
BE839744A (fr) 1976-09-20
FI61875B (fi) 1982-06-30
CH626057A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1981-10-30
FR2304336B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1979-09-28
CH629184A5 (de) 1982-04-15
SU620206A3 (ru) 1978-08-15
AT340895B (de) 1978-01-10
ZA761434B (en) 1977-10-26
US4085225A (en) 1978-04-18
HU171030B (hu) 1977-10-28
JPS51125345A (en) 1976-11-01
FR2304336A1 (fr) 1976-10-15
GB1535226A (en) 1978-12-13
CH629477A5 (de) 1982-04-30
SE410312B (sv) 1979-10-08
DE2610886C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1987-09-24
IL49238A (en) 1978-08-31
DK144942B (da) 1982-07-12
PL100614B1 (pl) 1978-10-31
CH629761A5 (de) 1982-05-14
IT1063064B (it) 1985-02-11
AR211011A1 (es) 1977-10-14
PL100052B1 (pl) 1978-08-31
AU1214776A (en) 1977-09-22
MX9203723A (es) 1992-07-01
FI61875C (fi) 1982-10-11
IE43768B1 (en) 1981-05-20
JPS6026776B2 (ja) 1985-06-25

Similar Documents

Publication Publication Date Title
DE2610886A1 (de) Verbindungen mit antidepressiver wirkung
DE3047142C2 (de) Basische 1,7,7-Trimethylbicyclo[2,2,1]heptyläther, Verfahren zur Herstellung derselben und diese enthaltende Arzneimittel
DD141520A5 (de) Verfahren zur herstellung neuer derivate von 4-amino-5-alkylsulfonyl-ortho-anisamiden
CH616676A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE3329628C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP0152868B1 (de) Isoxazol-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
AT396362B (de) 5,5-dimethyl-3-phenylvinyl-1-aminoalkoxy-iminocyclohex-2-enderivate
DE2609437C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE2611118C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE2609862C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE2610679C2 (de) Sulfinylgruppenhaltige Oximätherderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Mittel
DE2034588C3 (de) 6,7-Dimethoxy-4-benzylisochinoline, Verfahren zu ihrer Herstellung und Arzneimittel
DE3218743A1 (de) Isoprenylaminderivate und saeureadditionssalze davon
DE2615129A1 (de) Tripeptide, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
DE2421549A1 (de) Naphthalinderivate, verfahren zu ihrer herstellung und arzneimittel
DE2914801A1 (de) Benzylidenester, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
EP0413302A1 (de) Neue 1,3-Oxazine
DE2525164A1 (de) M-phenylen-dioxamate, verfahren zu deren herstellung und diese verbindungen enthaltende praeparate
DE1951614B2 (de) Substituierte Benzylalkohol, deren physiologisch verträgliche Salze, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DE3907512A1 (de) Neue aryloxy-alkylamine, deren herstellung und diese enthaltende arzneimittel
CH454147A (de) Verfahren zur Herstellung eines neuen Isoxazolderivates
DE2402989A1 (de) Neue benzylamine
CH532030A (de) Verfahren zur Herstellung von Oximäther
DE2416144A1 (de) Antiulcus-mittel

Legal Events

Date Code Title Description
8128 New person/name/address of the agent

Representative=s name: LEDERER, F., DIPL.-CHEM. DR. MEYER-ROXLAU, R., DIP

8110 Request for examination paragraph 44
8128 New person/name/address of the agent

Representative=s name: LEDERER, F., DIPL.-CHEM. DR., PAT.-ANW., 8000 MUEN

D2 Grant after examination
8364 No opposition during term of opposition